Evaluation of the Hybritech Tandem-R Ostase™ immunoradiometric assay for skeletal alkaline phosphatase

England, Thomas E.; Samsoondar, James; Maw, George

doi:10.1016/0009-9120(94)90054-x

Cited by 15 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone turnover markers were measured at baseline and after 1, 3, 6, 12, 24 and 36 months in subjects enrolled at a subset of study centers. Serum bone-specific alkaline phosphatase (BAP) was measured using the Hybritech Tandem-R Ostase immunoradiometric assay [19], and urinary deoxypyridinoline/ creatinine (Dpd/Cr) ratio using high-performance liquid chromatography [20]. The urine samples were to be 2-hr, fasting collections, obtained in the morning.…”

Section: Measurementsmentioning

confidence: 99%

Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis

Reginster

Minne²,

Sørensen

et al. 2000

Osteoporosis International

1,441

833

View full text Add to dashboard Cite

The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with established osteoporosis. The study was conducted at 80 study centers in Europe and Australia. Postmenopausal women (n = 1226) with two or more prevalent vertebral fractures received risedronate 2.5 or 5 mg/day or placebo; all subjects also received elemental calcium 1000 mg/day, and up to 500 IU/day vitamin D if baseline levels were low. The study duration was 3 years; however, the 2.5 mg group was discontinued by protocol amendment after 2 years. Lateral spinal radiographs were taken annually for assessment of vertebral fractures, and bone mineral density was measured by dual-energy X-ray absorptiometry at 6-month intervals. Risedronate 5 mg reduced the risk of new vertebral fractures by 49% over 3 years compared with control (p<0.001). A significant reduction of 61% was seen within the first year (p = 0.001). The fracture reduction with risedronate 2.5 mg was similar to that in the 5 mg group over 2 years. The risk of nonvertebral fractures was reduced by 33% compared with control over 3 years (p = 0.06). Risedronate significantly increased bone mineral density at the spine and hip within 6 months. The adverse-event profile of risedronate, including gastrointestinal adverse events, was similar to that of control. Risedronate 5 mg provides effective and well-tolerated therapy for severe postmenopausal osteoporosis, reducing the incidence of vertebral fractures and improving bone density in women with established disease.

show abstract

Section: Measurementsmentioning

confidence: 99%

Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis

Reginster

Minne²,

Sørensen

et al. 2000

Osteoporosis International

1,441

833

View full text Add to dashboard Cite

show abstract

“…Identified for full-paper screening 444; nine were unobtainable, [196][197][198][199][200][201][202][203][204] (one 200 was identified from a bibliography with the same journal details as a screened paper, 205 but a different title), 35 were reviews that underwent bibliographic screening, 5,6,11,15,34,47,50, and 42 were included. Of the remaining 358 studies, the reasons for exclusion are given below (some papers were excluded for more than one reason): Definition of osteoporosis: T-score at LS/hip ≤ -2.5…”

Section: Search Termsmentioning

confidence: 99%

Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups

Burch

Rice

Yang

et al. 2014

Health Technology Assessment

114

View full text Add to dashboard Cite

“…Both assays show a cross-reactivity of 14-20% with liver alkaline phosphatase (8)(9)(10)(11)(12). However, it is supposed that in patients with hepatobiliary diseases the measured bone alkaline phosphatase values stay within the reference range if total alkaline phosphatase activity does not exceed about twice the upper limit of the normal range (6).…”

Section: Technical Criteriamentioning

confidence: 99%

Review

1996

CCLM

View full text Add to dashboard Cite

A review is given summarizing the present knowledge of bone turnover markers with special emphasis on biological, preanalytical and technical criteria in the proper judgement of efficacy and limitations of the methods employed. The marker substances may be either measures of bone formation or bone resorption.Markers of bone formation are bone alkaline phosphatase, osteocalcin and the carboxyl-terminal propeptide of procollagen type I. Bone alkaline phosphatase has proved to be superior to total alkaline phosphatase activity with respect to diagnostic sensitivity and specificity. Immunochemical techniques for measuring bone alkaline phosphatase show a cross-reactivity of 14-20% with liver alkaline phosphatase. However, this does not compromise the clinical usefulness of these assays except for patients with severe liver diseases. Osteocalcin is strictly bone-specific but shows numerous disadvantages with respect to apparent instability and discordant results as obtained by different methods; however, in certain diagnostic situations (corticosteroid-induced osteopenia, absence of destroyed bone architecture) osteocalcin may serve as a sensitive bone turnover marker. The carboxyl-terminal propeptide of procollagen type I generally shows low discriminating power in the diagnosis of bone diseases.The urinary excretion of pyridinium 'cross-links' has been carefully evaluated so far with respect to analytical performance and clinical usefulness. This marker may be a substitute for 4-hydroxyproline measurements as the method of choice for assessment of bone resorption. There are other degradation products from the telopeptide regions of bone-derived collagen type I which are excreted into the urine (N-telopeptides, CrossLaps™)\ these analytes are promising tools in the assessment of bone resorption but require further evaluation, in particular with respect to their extraskeletal clearance and putative origin outside bone. Moreover, their clinical usefulness may vary depending on the patient group examined. In contrast, the serum concentration of the cross-linked telopeptide region of collagen type I seems to lack both diagnostic specificity and sensitivity in the majority of patient groups. Tartrate-resistant acid phosphatase (as determined by the presently available methods) cannot be recommended as a routine tool for assessment of bone resorption.Brought to you by | University of Arizona Authenticated Download Date | 7/8/15 5:47 AM

show abstract

Evaluation of the Hybritech Tandem-R Ostase™ immunoradiometric assay for skeletal alkaline phosphatase

Cited by 15 publications

References 4 publications

Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis

Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis

Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups

Review

Contact Info

Product

Resources

About